摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-chloro-5-(8-oxo-6-thioxo-5-(p-tolyl)-5,7-diazaspiro[3.4]octan-7-yl)picolinonitrile | 1332389-34-0

中文名称
——
中文别名
——
英文名称
3-chloro-5-(8-oxo-6-thioxo-5-(p-tolyl)-5,7-diazaspiro[3.4]octan-7-yl)picolinonitrile
英文别名
3-Chloro-5-[5-(4-methylphenyl)-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]pyridine-2-carbonitrile
3-chloro-5-(8-oxo-6-thioxo-5-(p-tolyl)-5,7-diazaspiro[3.4]octan-7-yl)picolinonitrile化学式
CAS
1332389-34-0
化学式
C19H15ClN4OS
mdl
——
分子量
382.873
InChiKey
LXQNQKILHKWWKM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.7
  • 重原子数:
    26
  • 可旋转键数:
    2
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.26
  • 拓扑面积:
    92.3
  • 氢给体数:
    0
  • 氢受体数:
    4

文献信息

  • [EN] ANDROGEN RECEPTOR MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS DU RÉCEPTEUR DES ANDROGÈNES ET LEURS UTILISATIONS
    申请人:ARAGON PHARMACEUTICALS INC
    公开号:WO2011103202A2
    公开(公告)日:2011-08-25
    Described herein are compounds that are androgen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such androgen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon androgen receptors.
    本文介绍的是雄激素受体调节剂化合物。还描述了包括所述化合物的制药组合物和药物,以及使用这种雄激素受体调节剂,单独或与其他化合物结合使用,治疗与雄激素受体有关或依赖于雄激素受体的疾病或病症的方法。
  • ANDROGEN RECEPTOR MODULATORS AND USES THEREOF
    申请人:Smith Nicholas D.
    公开号:US20130116258A1
    公开(公告)日:2013-05-09
    Described herein are compounds that are androgen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such androgen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon androgen receptors.
    本文描述了一些雄激素受体调节剂化合物。还描述了包括上述化合物的药物组合物和药物,以及使用这些雄激素受体调节剂,单独或与其他化合物组合使用,治疗与雄激素受体相关或依赖的疾病或病症的方法。
  • COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AND ASSOCIATED METHODS OF USE
    申请人:Arvinas Operations, Inc.
    公开号:US20220144809A1
    公开(公告)日:2022-05-12
    Bifunctional compounds, which find utility as modulators of androgen receptor (AR), are described herein. In particular, the bifunctional compounds of the present disclosure contain on one end a moiety that binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds AR, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The bifunctional compounds of the present disclosure exhibit a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aberrant regulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
    本文描述了具有雄激素受体(AR)调节剂作用的双功能化合物。特别地,本公开的双功能化合物在一端含有结合到cereblon E3泛素连接酶的基团,在另一端含有结合到AR的基团,使得靶蛋白质位于泛素连接酶附近以促进靶蛋白质的降解(和抑制)。本公开的双功能化合物表现出与靶蛋白质的降解/抑制相关的广泛的药理活性。使用本公开的化合物和组合物治疗或预防由靶蛋白质异常调节引起的疾病或障碍。
  • Androgen receptor modulators and uses thereof
    申请人:Aragon Pharmaceuticals, Inc.
    公开号:EP2824102A1
    公开(公告)日:2015-01-14
    Described herein are compounds (Ia) that are androgen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such androgen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon androgen receptors. The treatment of cancer is claimed.
    本文描述的化合物(Ia)是雄激素受体调节剂。还描述了包括本文所述化合物的药物组合物和药物,以及单独或与其他化合物结合使用这种雄激素受体调节剂治疗介导或依赖于雄激素受体的疾病或病症的方法。 要求治疗癌症。
  • COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR
    申请人:Arvinas Operations, Inc.
    公开号:EP3660004A1
    公开(公告)日:2020-06-03
    The present disclosure relates to bifunctional compounds, which find utility to degrade and (inhibit) Androgen Receptor. In particular, the present disclosure is directed to compounds, which contain on one end a cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds Androgen Receptor, such that Androgen Receptor is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of Androgen Receptor. The present disclosure exhibits a broad range of pharmacological activities associated with compounds according to the present disclosure, consistent with the degradation/inhibition of Androgen Receptor.
    本公开涉及双功能化合物,它们可用于降解和(抑制)雄激素受体。特别是,本公开涉及的化合物一端含有与 E3 泛素连接酶结合的脑龙配体,另一端含有与雄激素受体结合的分子,这样雄激素受体就被置于泛素连接酶附近,从而实现对雄激素受体的降解(和抑制)。本公开的化合物具有广泛的药理活性,与雄激素受体的降解/抑制作用相一致。
查看更多

同类化合物

(R)-4-异丙基-2-恶唑烷硫酮 麻黄恶碱 顺-八氢-2H-苯并咪唑-2-酮 顺-1-(4-氟苯基)-4-[1-(4-氟苯基)-4-羰基-1,3,8-三氮杂螺[4.5]癸-8-基]环己甲腈 非达司他 降冰片烯缩醛3-((1S,2S,4S)-双环[2.2.1]庚-5-烯-2-羰基)恶唑烷-2-酮 阿齐利特 阿那昔酮 阿洛双酮 阿帕鲁胺 阿帕他胺杂质2 铟烷-2-YL-甲基胺盐酸 钾3-{2-[3-氰基-3-(十二烷基磺酰基)-2-丙烯-1-亚基]-1,3-噻唑烷-3-基}-1-丙烷磺酸酯 钠2-{[4,5-二羟基-3-(羟基甲基)-2-氧代-1-咪唑烷基]甲氧基}乙烷磺酸酯 重氮烷基脲 詹氏催化剂 解草恶唑 解草噁唑 表告依春 螺莫司汀 螺立林 螺海因氮丙啶 螺[咪唑烷-4,3'-吲哚啉]-2,2',5-三酮 螺[1-氮杂双环[2.2.2]辛烷-8,5'-咪唑烷]-2',4'-二酮 苯甲酸,4-氟-,2-[5,7-二(三氟甲基)-1,8-二氮杂萘-2-基]-2-甲基酰肼 苯氰二硫酸,1-氰基-1-甲基-4-氧代-4-(2-硫代-3-噻唑烷基)丁酯 苯妥英钠杂质8 苯妥英钠 苯妥英-D10 苯妥英 苯基硫代海因半胱氨酸钠盐 苯基硫代乙内酰脲-谷氨酸 苯基硫代乙内酰脲-蛋氨酸 苯基硫代乙内酰脲-苯丙氨酸 苯基硫代乙内酰脲-色氨酸 苯基硫代乙内酰脲-脯氨酸 苯基硫代乙内酰脲-缬氨酸 苯基硫代乙内酰脲-异亮氨酸 苯基硫代乙内酰脲-天冬氨酸 苯基硫代乙内酰脲-亮氨酸 苯基硫代乙内酰脲-丙氨酸 苯基硫代乙内酰脲-D-苏氨酸 苯基硫代乙内酰脲-(NΕ-苯基硫代氨基甲酰)-赖氨酸 苯基乙内酰脲-甘氨酸 苏氨酸-1-(苯基硫基)-2,4-咪唑烷二酮(1:1) 色氨酸标准品002 膦酸,(2-羰基-1-咪唑烷基)-,二(1-甲基乙基)酯 脱氢-1,3-二甲基尿囊素 脱氢-1,3,8-三甲基尿囊素 聚(d(A-T)铯)